Replies to post #142401 on Biotech Values

[BTH]

Is the P3 metmab trial one with a diagnostic for high-low met pts?

The P3 Arq trial is non-squ NSCLC but without a diagnostic?

Either way, I think the MARQUEE study will be a success....but, generally, when a stock declines from 8.50 to 5.40 with a constant drip of 3% daily, and 18 out of 20 days "red", I am missing something, or someone leaked something.

[Summer2762]

I think investors expected a little bit better HCC data. At least I did. That might be the reason of the latest weakness.